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Abstract
RET/PTC and CK19 Expression in Papillary Carcinoma and 
Its Clinicopathologic Correlation
Eunah Shin
Department of Medicine 
The Graduate School, Yonsei University
(Directed by Professor Woo Ick Yang)
   Papillary thyroid carcinoma (PTC) is the most common malignancy 
arising in the thyroid, with an excellent long-term survival rates. Its 
diagnosis has rested on the characteristic nuclear features, but problem 
arises with unequivocal cytologic features that are present focally or 
multifocally. Although controversial, CK19 has been reported to be a 
useful ancillary tool for diagnosing papillary carcinoma of the thyroid. 
   Recently, the rearrangement of RET proto-oncogene has been 
reported to be the most common genetic change in the development of 
PTC. However, its prevalence has been reported variably and its 
correlation with clinical outcome has been controversial.
   To evaluate the expression rate of RET/PTC rearrangement and 
CK19 in papillary thyroid carcinoma in a Korean population and its 
clinicopathologic correlation, we studied 115 papillary thyroid 
carcinomas in 3mm-core tissue microarray based immunohistochemical 
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analysis.  
   The prevalence of Ret protein expression was 62.6% (72 out of 115 
cases) and the CK19 immunoreactivity was 80.9% (93 out of 115 
cases) in papillary thyroid carcinomas, which were in accord with those 
in Western countries. There was no statistically significant associations 
between the Ret positivity and CK19 immunoreactivity, although the 
percent agreement of the two was relatively high. The 
clinicopathological variables, i.e. age, sex, size of the tumor, regional 
lymph node metastasis, perithyroidal extension, and multiplicity, did not 
correlate with the expression of Ret. 
   In conclusion, the prevalence of Ret protein expression and its 
clinicopathological implications in a Korean population are not different 
from those reported in previous studies. However, its detection via 
immunohistochemistry can be a useful diagnostic tool for diagnosing 
papillary thyroid carcinoma in conjunction with CK19. 
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Key words: thyroid carcinoma, Ret protein, cytokeratin 19, Korea,
           immunohistochemistry, tissue microarray
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RET/PTC and CK19 Expression in Papillary Thyroid 
Carcinoma and Its Clinicopathologic Correlation
<Directed by Professor Woo Ick Yang>
Department of Medical Science
The Graduate School of Yonsei University
Eunah Shin
I. INTRODUCTION
   Papillary thyroid carcinoma (PTC) is the most common malignancy 
arising in the thyroid, with an excellent long-term survival rates of 
more than 90%.1 Its pathogenesis is associated with previous exposure 
to ionizing radiation, both external and internal.2 Several genes have 
been implicated in the carcinogenesis of PTC, including TP53, p21, 
met, trk and ras.3,4 Recently, however, the rearrangement of RET 
proto-oncogene, which is normally expressed in neural crest-derived 
tissues but not in thyroid follicular cells, has been reported to be the 
most common genetic change in the development of PTC.5 The RET 
proto-oncogene maps to the long arm of chromosome 10 and encodes a 
cell membrane-bound receptor tyrosine kinase.6  When the tyrosine 
kinase encoding domain of the RET proto-oncogene undergoes fusion 
with the 5'-terminal region of another gene that is constitutively 
expressed, it results in activation of an oncogene designated RET/PTC. 
As a consequence, the products of the chimeric RET/PTC oncogenes 
- 4 -
lead to the relocation of the ret tyrosine kinase domain from the 
membrane to the cytoplasm and display constitutive tyrosine-kinase 
activity by autophosphorylation.7-11
   Such rearrangements of the RET proto-oncogene have only been 
found in thyroid gland tumors of the papillary histotype.  However, its 
prevalence has been reported variably in different geographical 
regions,12-16 and its correlation with clinical outcome has been 
controversial.2,7,17-19 
   Identification of a patient subgroup with potential for developing 
aggressive disease is important, for the appropriate use of adjuvant 
therapy is harbored on such identification. The problem arises when 
patients lacking the previously established poor prognostic factors, i.e. 
age greater than 40, tumor size greater than 5cm, multicentricity, blood 
vessel invasion, extrathyroidal extension, distant metastasis, and 
aneuploidy, or the histological subtype develop aggressive disease. Thus, 
the study of oncogene and tumor suppressor gene expression may be 
useful in identifying additional reliable prognostic factors.      
   Recent studies of cytokeratin expression in thyroid neoplasms have 
demonstrated that various low and high molecular-weight cytokeratins in 
general are expressed differentially in papillary thyroid carcinoma.20,21 In 
particular, cytokeratin (CK) 19 is reported to be limited to papillary 
carcinomas, thus favoring a diagnosis of papillary carcinoma in all its 
variant patterns.22 Sahoo et al. has reported that immunoreactivity for 
CK19 is not specific for PTC, although the extent and intensity of 
staining are significantly greater in PTC than in follicular adenoma.23 
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However, most of the previous studies have proposed CK19 to be a 
useful immunohistochemical marker to distinguish PTC from other 
benign and malignant follicular lesions.21,24,25
   The purpose of this current study is first to evaluate the expression 
rate of Ret protein in a large series of classic papillary thyroid 
carcinomas in a Korean population using immunohistochemistry in 
tissue microarray and explore the possibility of Ret protein expression 
as a reliable prognostic factor. Secondly, this study is intended to 
clarify a more specific role of Ret antibody as an ancillary tool for 
diagnosing papillary carcinoma in conjunction with CK19.
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II. MATERIALS AND METHODS
  
1. Patient Selection
  The surgical pathology files of Yonsei University Severance Hospital 
in the year 2001 were searched for 'papillary carcinoma' in thyroid. 
After review of the search results, a consecutive series of 115 classic 
papillary thyroid carcinomas, with all variants including follicular variant 
excluded, were selected for the study. Clinical data were obtained from 
the medical records.
2. Histopathology, Tissue microarray construction, and               
   Immunohistochemistry
   The slides of 115 cases were reviewed with special attention to the 
diagnostic nuclear features of papillary thyroid carcinoma, i.e. nuclear 
grooves, intranuclear inclusions and nuclear clearing1, and papillary 
structures to identify representative areas of the specimen for tissue 
microarray. From these defined areas core biopsies were taken with a 
precision instrument. Tissue cores with a diameter of 3mm from each 
specimen were punched and arrayed on a recipient paraffin block. 
Four-μm sections of these tissue array blocks were cut and used for 
immunohistochemical analysis (Figure 1). Normal thyroid tissue distant 
from the i) tumor area, ii) adenomatous nodule, and iii) inflammatory 
cell infiltrates were obtained from each specimen and arrayed. These 
arrayed normal tissues served as baseline controls. 
   Sections from tissue arrays were deparaffinized in xylene, rehydrated 
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in graded alcohols, and processed using the labeled streptavidin - biotin 
- peroxidase method. Briefly, sections were submitted to antigen 
retrieval for 15 minutes in 44% formic acid for Ret and in 0.4% 
pepsin for CK19, both at room temperature. Slides were subsequently 
incubated in 10% normal blocking serum for 30 minutes. They were 
then incubated overnight at 4℃ in appropriately diluted primary 
antibody. Rabbit polyclonal antibody Ret (1:200; Santa Cruz 
Biotechnology, Santa Cruz, California, USA) and mouse monoclonal 
antibody CK19 (1:75; Biomeda, Hayward, California, USA) were used. 
After washing with Tris buffer, sections were incubated with 
biotin-labelled secondary antibodies and then with streptavidin - 
horseradish peroxidase using the DAKO LSAB kit (DAKO, Carpinteria, 
California, USA) at room temperature for 30 minutes for each step. 
Nova red (Vector Laboratory, Burlingame, California, USA) was used 
as the chromogen and hematoxylin as the nuclear counterstain. This 
procedure was performed for all antibodies under study. 
   The sections were also stained with antibodies to thyroglobulin 
(1:500, DAKO, Glostrup, Denmark), thyroid transcription factor-1 
(1:100, DAKO, Glostrup, Denmark), and calcitonin (1:200, DAKO, 
Glostrup, Denmark) to validate the follicular cell origin of each case.
   Diffuse cytoplasmic staining of more than 30% of the tumor cells 
was defined as positive immunoreactivity for Ret and CK19. 
   Informations on regional lymph node metastasis, perithyroidal 
extension of the tumor, multiplicity at the time of diagnosis, and size 
of the tumor were assessed from the surgical pathology reports.
- 8 -
3. Statistical Analysis
   Summary statistics were obtained using established methods.26 
Associations between Ret immunoreactivity and each variable, i.e. 
lymph node metastasis, perithyroidal extension and multiplicity, were 
evaluated using the chi-square test. Kappa statistics was performed for 
the evaluation of percent agreement, the extent to which Ret 
immunoreactivity and CK19 immunoreactivity concur, in classic 
papillary carcinoma. 
   In all statistical analyses, a two-tailed p value ≤ 0.05 was 
considered statistically significant. All analyses were performed using 
SPSS for Windows statistical software (Version 10.0). 
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III. RESULT
1. Clinicopathological data
   The male to female sex ratio of the patient group was 1:10.5, 
which was similar in both Ret positive and negative groups. The 
average age at surgery was 44.5 years, with a range from 19 - 76 
years (Table 1). Twenty-nine patients had multifocal disease, and 84 
patients had single tumors. Information on the multiplicity of the tumor 
at the time of the surgery was not available in two patients. The 
average tumor size was 1.8cm with a range from 0.5 - 6.0cm. The size 
of the tumor was not mentioned in the surgical pathology reports in 6 
patients. Of the remaining 109 tumors, 37 cases were less than 1cm, 
68 were in the range of 1 - 4cm, and only 4 cases were more than 
4cm (Table 2). Eighty-five patients underwent regional lymph node 
dissection, of which 63 had lymph node metastasis.  Perithyroidal 
extension was present in 84 cases and 29 cases had tumors confined to 
the thyroid parenchyma (Table 2). The presence of perithyroidal 
extension was not evaluable in two cases, for perithyroidal soft tissue 
was not included within the specimen. 
2. RET protein expression by immunohistochemistry and             
   clinicopathologic correlation
   A total of 72 cases (62.6%) of 115 papillary thyroid carcinomas 
expressed Ret protein. The immunohistochemical detection of Ret 
protein was consistently observed in the cytoplasm of the tumor cells in 
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more than 30% of the tissue core for each case. Ret protein expression 
was absent in the normal thyroid tissues (Figure 3). 
   The Ret protein expression rate was not different in those groups 
with and without regional lymph node metastasis, perithyroidal 
extension, and multifocal disease (Table 2). Furthermore, age and sex 
of the patient group (Table 1), and the size of the tumor did not 
influence the expression of Ret (Table 2). 
3. CK19 and Ret protein expression
   Ninety-three papillary carcinomas (80.9%) showed diffuse 
cytoplasmic staining of CK19 (Table 3) (Figure 4). As with the Ret 
protein expression, CK19 immunoreactivity also had no statistically 
significant correlation with the aforementioned clinicopathological 
variables. Of the 115 cases, 7 cases were in lack of normal thyroid 
tissue in the specimen and 12 out of the 108 matched normal thyroid 
tissue showed CK19 immunoreactivity in the follicular epithelial cells. 
   Of the 115 papillary carcinomas, 62 (53.9%) showed positivity for 
both CK19 and Ret, and twelve (10.4%) showed negative results for 
both CK19 and Ret. The percent agreement of the two antibodies in 
classic papillary carcinomas was relatively high, however, it had no 
statistical significance (κ=0.16, p=0.06) (Table 3). 
   
Table 1. Clinical data and their correlation with Ret protein
          expression in papillary carcinoma         
Ret
 p-value
Positive Negative
Age (yr)
  Mean
  Range
     ≤40
      >40
44.5±13.4
 19 - 76
        43
 72
45.1±13.2
20 - 68
24(55.8%)
48(66.7%)
43.6±13.8
19 -76
19(16.5%)
24(33.3%)
p=0.55
Sex 
  Female
  Male
 105
 10
66(62.9%)
6(60.0%)
39(37.1%)
4(40.0%)
p=1.00
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Table 2. Clinicopathologic variables and correlation with 
          Ret protein expression in papillary carcinoma
Ret
p-value Total
Positive Negative
LN metastasis 1.00
Yes 40(63.5%) 23(36.5%) 63(74.1%)
No 14(63.6%) 8(36.4%) 22((25.9%)
 Perithyroidal   
  extension
1.00
Yes 52(61.9%) 32(38.1%) 84(74.3%)
No 18(62.1%) 11(37.9%) 29(25.7%)
 Multiplicity 0.50
Yes 20(69.0%) 9(31.0%) 29(25.7%)
No 50(59.5%) 34(40.5%) 84(74.3%)
 Size (cm)
Mean 1.7±1.1 2.0±1.1 0.31 1.8±1.1
   ≤1cm 25(67.6%) 12(32.4%) 37(33.9%)
   1-4cm 40(58.8%) 28(41.2%) 68(62.4%)
   〉4cm 3(75.0%) 1(25.0%) 4(3.7%)
-12-
Table 3. Percent agreement of Ret and CK19          
          immunoreactivity in papillary carcinoma
CK19 Total
Positive Negative
Ret
Positive 62 (53.9%) 10 (8.7%) 72
 Negative 31 (27.0%) 12 (10.4%) 43
Total 93 22
-13-
Figure 1. Top: 4-μm section of tissue microarray stained with 
                H&E, showing 3mm cores of papillary thyroid     
                carcinomas and matched normal thyroid tissues.
     
           Center: Immunohistochemical stain for Ret antibody.
           Bottom: Immunohistochemical stain for CK19.
-14-
Figure 2. H&E sections of papillary 
  carcinomas and normal thyroid tissue   
  in the tissue microarray. 
  
  Upper: papillary carcinoma showing    
    papillary structure (left, x200) and   
    unequivocal nuclear features         
    (right, x400)
  
 Lower: normal thyroid tissue
-15-
Figure 3. a) Diffuse cytoplasmic staining of the Ret antibody in the tumor   
             tissue(x200) b) no immunoreactivity in the matched normal thyroid  
             tissue(x100)
Figure 4. a) Diffuse cytoplasmic staining of the tumor cells for CK19(x200)  
            b) no immunoreactivity in the matched normal thyroid tissue(x100)
-16-
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IV. DISCUSSION
   The RET proto-oncogene has been identified to be responsible for 
the inherited cancer syndrome MEN 2, and also involved in the 
molecular pathogenesis of sporadic medullary thyroid carcinomas,   
papillary thyroid carcinomas, and Hirschsprung's disease.27
   In the pathogenesis of papillary thyroid carcinoma (PTC), RET 
activation has been hypothesized to constitute a specific genetic event 
and to account for the characteristic nuclear changes of PTC.28 Sugg et 
al. identified RET/PTC rearrangements in the majority of occult 
papillary microcarcinomas and lower percentage of rearrangements in 
clinically manifest tumors, suggesting a significant role of RET/PTC 
rearrangements in the initiation of papillary carcinoma.  However, the 
exact role of RET/PTC in the development of papillary carcinoma 
remains unclear and the prevalence of RET/PTC rearrangement is 
ill-defined, varying widely from 2.5-34.5% among patient series from 
different geographical regions.12-16 The existence of geographic 
variability is shown by comparison of the prevalence of RET/PTC 
activation in different studies of sporadic papillary carcinomas, all of 
which have used reverse transcriptase polymerase chain reaction.14,29,30,36 
Santoro et al. found 11% in the French samples, 33% in the Italian 
samples, and 17% in the U.S. tumors.7 These discordant results may be 
due in part to the different methods and sensitivity of the techniques 
used, as well as the influence of environmental factors such as ionizing 
radiation exposure. There have been two published data in Korea prior 
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to this current study. Park et al., in 1998, found no RET/PTC-1, -2, or 
-3 rearrangement in 24 cases of papillary carcinoma by RT-PCR in a 
Korean population31, whereas Chung et al. reported a prevalence of 
12.9% in Korean papillary thyroid carcinomas.32 The latter authors 
found four out of thirty-one papillary thyroid carcinomas to be positive 
for RET/PTC rearrangement by RT-PCR, two of which were positive 
for RET/PTC-2 and the remaining two were positive for RET/PTC-3, 
and concluded that the prevalence of RET/PTC rearrangement in 
Korean population is not different from that of other Western countries.  
   Although the method of detection was different, the frequency of 
RET/PTC expression in our study was higher than in those two studies. 
By immunohistochemistry, we found 72 cases out of 115 classic 
papillary thyroid carcinomas (62.6%) to be positive for Ret protein 
expression, which is also in accord with previous results in Western 
countries employing immunohistochemistry as the method of detection.33
   The immunohistochemical analysis on 3mm-core tissue microarray in 
our study can be reliably used to overcome the problem of tumor 
heterogeneity in protein expression throughout the entire tumor 
specimen. According to the recently published data on validation of 
tissue microarrays for immunohistochemical profiling of cancer 
specimens by Hoos et al.34, the concordance of data between full tissue 
sections and tissue microarray was the highest with triplicate 0.6mm 
cores (96 - 98%) when compared with one and two 0.6mm tissue 
cores. However, even with the one core analysis, the nonconcordance 
rate was only 9.4 - 11.4%.34 When the larger size of our tissue core 
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and the relatively smaller size of papillary carcinoma in general are 
taken into consideration, the validity of our immunohistochemical 
analysis on tissue microarray need not be in doubt.                   
   Immunohistochemical staining using antibodies against the RET 
tyrosine kinase domain for the detection of RET/PTC in papillary 
carcinomas is based on the assumption that since Ret is not expressed 
in thyroid follicular cells lacking RET/PTC activation, negative RET-TK 
immunoreactivity is consistent with lack of RET/PTC rearrangement.35,36  
Furthermore, a good correlation has been shown between 
immunohistochemical reactivity for RET-TK and RT-PCR.17,18,36 
However, the discrepancy in results between groups employing 
RT-PCR/in situ hybridization and those using immunohistochemistry 
may be explained by the existence of wild-type RET oncogene. In 
addition to RET/PTC 1, 2, and 3 and their variants, it is probable that 
wild-type RET oncogene activation plays a role in the development of 
PTC. The fact that positive immunoreactivity for RET oncogene not 
only detects the product of RET/PTC oncogenes, but also the products 
of wild-type RET may account for the high rate of Ret protein 
immunoreactivity. 
   Many attempts have been made to correlate the presence of 
RET/PTC activation with the clinical parameters of human papillary 
thyroid carcinomas. Our results demonstrate that the Ret protein 
expression is not influenced by any of the clinicopathologic parameters, 
i.e. age, sex, size of the tumor, multiplicity, lymph node metastasis, and 
perithyroidal extension. Jhiang et al proposed that RET/PTC may be 
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associated with distant metastatic disease, as 2 of 4 (50%) tumors that 
had distant metastases expressed RET/PTC rearrangements compared to 
4 of 32 (12%) tumors that did not metastasize.15 Miki et al. found a 
higher incidence of RET/PTC expression in cases with extrathyroidal 
invasion than in those without invasion by immunohistochemistry (68% 
vs. 20%, p<0.01), suggesting that RET/PTC may be related to the local 
invasion of papillary carcinomas.19 However, other investigators have 
shown that RET/PTC is more frequently detected in smaller, slow 
growing, and less aggressive PCs, proposing that RET/PTC may serve 
as a marker for favorable prognosis.37,38 It has also been suggested that 
RET/PTC positivity correlates with early lymph node spread but lower 
metastatic potential.29,39,40 This discrepancy may be explained by the 
differences in screening methods, sample preparation, genetic 
background of patients, and environmental factors. Thus, it is difficult 
to compare reports that have studied different patient populations and 
used different approaches to detect RET/PTC rearrangements. Also, it is 
yet to be determined whether the clinical behavior of human PC is 
affected by differences in RET/PTC expression levels, and/or the 
different forms of RET/PTC. It is conceivable that signaling pathways 
perturbed by RET/PTC activation in thyroid cells could be overcome by 
other factors, if RET/PTC expression occurs at a low level.41
   Although papillary thyroid carcinomas have the propensity for 
regional lymph node metastasis, most of the patients have an excellent 
long-term survival rates. Such excellent prognosis rests on the 
appropriate treatment at the right time, which makes it imperative for 
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the pathologists to render an accurate diagnosis. However, identification 
of the cytologic features that are diagnostic of papillary carcinoma can 
be controversial, especially when these features are present focally or 
multifocally rather than diffusely throughout the lesion, or when the 
tumors assume non-papillary architecture, i.e. follicular variant of the 
papillary carcinoma.     
   Immunohistochemical investigation of papillary thyroid neoplasm had 
detected many markers for papillary thyroid carcinomas that have 
varying degrees of sensitivity and specificity for this neoplasm. The 
markers that appear to yield a high sensitivity and specificity include 
high molecular weight cytokeratin (AE3)40, HBME, CD57 and 
CD15.42-45 CK19 and high molecular weight cytokeratin were reported 
to be reactive in most papillary thyroid carcinomas.20,21,24 The findings 
of our study showed 80.9% positivity in the 115 classic papillary 
thyroid carcinomas, which are in corroboration of previous reports that 
CK19 immunohistochemistry is a useful ancillary tool for diagnosing 
papillary carcinoma of the thyroid.23,46,47 Cheung et al. have reported 
that CK19 and Ret antibody comprise an excellent diagnostic panel for 
papillary thyroid carcinoma along with HBME-1.33 However, they did 
not show the percent agreement of the two antibodies in 
immunoreactivity. We have found 62 (53.9%) out of 115 papillary 
carcinomas to be positive for both Ret and CK19, implicating a 
relatively high percent agreement of the two antibodies in diagnosing 
papillary carcinoma. However, it was statistically not significant 
(p=0.06, κ=0.16), due in part to comparatively high percentage of 
- 22 -
positive immunoreactivity for CK19. 
   Although none of the clinicopathological parameters showed any 
correlation with Ret protein expression in our cohort of 115 classic 
papillary thyroid carcinomas, RET/PTC oncogene activation is a marker 
for papillary thyroid carcinoma with potentially useful applications to 
the diagnosis of clinically suspicious thyroid lesions with questionable 
cytologic features of papillary carcinoma as well as to the follow-up of 
patients. Larger patient numbers and longer follow-up times may 
provide additional information in future studies. 
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V. CONCLUSION
   RET protein expression and CK19 immunoreactivity were analyzed 
in 115 classic papillary thyroid carcinomas in Korea via tissue 
microarray. 
   1. The prevalence of RET protein expression detected by           
      immunohistochemistry was 62.6% (72 out of 115 cases), which  
      was in accord with that in Western countries. 
   2. The clinicopathological variables, i.e. age, sex, size of the tumor,  
      regional lymph node metastasis, perithyroidal extension, and  
      multiplicity, did not correlate with the expression of RET. 
   3. CK19 immunoreactivity was 80.9% (93 out of 115 cases) in     
      papillary thyroid carcinomas, which was slightly higher but      
      similar to that in Western countries. 
   4. The percent agreement of Ret positivity and CK19              
      immunoreactivity was relatively high, but statistically not        
      significant.
   In conclusion, the prevalence of RET protein expression and its 
clinicopathological implications in a Korean population are not different 
from those reported in previous studies. However, its detection via 
- 24 -
immunohistochemistry can be a useful diagnostic tool for diagnosing 
papillary thyroid carcinoma in conjunction with CK19. 
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국문요약
갑상선 유두암에서 RET/PTC 와 CK19의 발현 및 임상적 의의
   갑상선 유두암은 갑상선 종양 중 가장 흔한 것으로서 그 예후가 
매우 좋은 것으로 알려져 있다. 갑상선 유두암은 그에 특이한 세포학적 
형태, 특히 핵의 모양이 진단적인 것으로 되어왔으나 그러한 
세포형태가 애매하거나 부분적으로만 존재할 경우에 진단에 어려움이 
생기게 된다. 이러한 문제에 대한 해결책의 일환으로 여러 가지 
면역화학적 표지자들이 연구되어왔으며 이 중에서도 그 특이성에 
대하여 아직 논란은 있지만 CK19가 갑상선 유두암의 진단에 가장 
유용하다는 보고들이 알려져 있다. 
   최근 갑상선 유두암의 발생에 관여하는 유전자 단계의 변화 중 가장 
흔한 것으로 RET 원종양유전자의 재배열이 보고되었으나 이의 빈도는 
지역마다 차이가 있는 것으로 보고되어 왔으며 임상적 예후와의 
관련성도 보고마다 많은 차이가 있다. 한국인의 갑상선 유두암에서 
RET/PTC 재배열의 빈도 역시 보고마다 차이가 있으며 임상적 예후와의 
관련성은 아직 보고된 바가 없는데 이를 위하여 저자는 3mm-core 
tissue microarray를 사용하여 115개의 한국인 갑상선 유두암에서 Ret 
과 CK19의 면역화학적 분석을 통하여 그 발현 빈도와 임상적 변수와의 
연관성을 연구하였다. 
   115개의 갑상선 유두암 중 62.6%인 72개에서 Ret에 대하여 
양성이었고 80.9%인 93개에서 CK19에 양성반응을 보였으며 이러한 
빈도는 서방에서의 면역화학적 연구결과와 일치하는 것이었다. Ret과 
CK19의 일치도는 비교적 높은 비율을 보였으나 통계학적으로 의의는 
없는 것이었다. 또한 환자의 나이나 성별, 종양의 크기, 주변 
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임파선으로의 전이 여부, 주위조직으로의 침윤 여부, 그리고 종양의 
다발성등과 Ret의 발현과는 연관성이 없는 것으로 나타났다. 
   결론적으로 한국인의 갑상선 유두암에서 Ret 단백의 발현 빈도와 
임상적 변수와의 연관성은 지금까지의 보고와 큰 차이가 없으나 Ret에 
대한 면역화학적 염색은 CK19와 함께 갑상선 유두암의 진단에 있어 
유용하게 사용될 수 있을 것으로 사료된다. 
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